


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (*currently amended*): A peptide according to formula (I) or a salt thereof:



wherein:

amino acid positions are numbered 1-14 and each amino acid may be a D- or L-amino acid;

A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamic acid which -is derivatized at the  ~~$\alpha$ -amino nitrogen~~N-terminus with a substituted benzoyl group selected from the group consisting of 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl, 3-bromobenzoyl, 4-bromobenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, and 4-nitrobenzoyl, or A1 is absent;

A2 is arginine or glutamic acid when A1 is arginine, lysine, ornithine, citrulline, alanine or glutamic acid, or,

if A1 is absent, A2 is arginine or glutamic acid derivatized at the N-terminus  ~~$\alpha$ -amino nitrogen~~ with a substituted benzoyl group selected from the group consisting of 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl, 3-bromobenzoyl, 4-bromobenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, and 4-nitrobenzoyl;

A3 is an aromatic amino acid;

A4 and A5 independently is arginine, lysine, ornithine, citrulline, alanine or glutamic acid;

A6 is proline, glycine, ornithine, lysine, alanine, citrulline, arginine or glutamic acid;

A7 is proline, glycine, ornithine, lysine, alanine, citrulline or arginine;

A8 is tyrosine, phenylalanine, alanine, naphthylalanine, citrulline or glutamic acid;

A9 is arginine, lysine, ornithine, citrulline, alanine or glutamic acid;

A10 is citrulline, glutamic acid, arginine or lysine;

A11 is arginine, glutamic acid, lysine or citrulline or a C-terminal derivative thereof; and the cysteines at positions 4 and 13 are optionally disulfide-bonded.

2. (*currently amended*): The peptide according to claim 1, wherein:

A1 is arginine, citrulline, alanine or glutamic acid which is derivatized at the N-terminus with a substituted benzoyl group selected from the group consisting of 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl, 3-bromobenzoyl, 4-bromobenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, and 4-nitrobenzoyl  ~~$\alpha$ -amino-nitrogen~~, or A1 is absent;

A2 is arginine or glutamic acid when A1 is an arginine, citrulline, alanine or glutamic acid ,  
or,

if A1 is absent, A2 is arginine or glutamic derivatized at the N-terminus  ~~$\alpha$ -amino-nitrogen~~  
with a substituted benzoyl group selected from the group consisting of  
2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl,  
3-bromobenzoyl, 4-bromobenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, and  
4-nitrobenzoyl;

A4 is arginine, citrulline, alanine or glutamic acid;

A5 is arginine, citrulline, alanine, lysine or glutamic acid;

A6 is lysine, alanine, citrulline or glutamic acid;

A7 is proline or alanine;

A8 is tyrosine, alanine or glutamic acid;

A9 is arginine, citrulline or glutamic acid;

A10 is citrulline or glutamic acid; and

A11 is arginine or glutamic acid or a C-terminal derivative thereof.

3. (*withdrawn; currently amended*): The peptide according to claim 1, wherein A1 is glutamic acid which is derivatized at the N-terminus  ~~$\alpha$ -amino-nitrogen~~, or A1 is absent.

#### 4. CANCELLED

5. (*withdrawn*): The peptide according to claim 1, wherein any one of A2, A4, A6, A8, and A9 is glutamic acid.

#### 6. CANCELLED

7. (*withdrawn*): The peptide according to claim 1, wherein A5 is arginine or glutamic acid.

8. (*withdrawn*): The peptide of claim 7 or a salt thereof, wherein A5 is glutamic acid.

9. (*withdrawn*) : The peptide according to claim 1, wherein A10 is glutamic acid, arginine or lysine.

10. *(withdrawn)*: The peptide according to claim 1, wherein A11 is glutamic acid, lysine or citrulline.

**11 to 13. CANCELLED**


14. *(withdrawn)*: A peptide having the sequence as set forth in any one of SEQ ID NOs: 11-68, or a salt thereof:

- (1) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:11);
- (2) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:12);
- (3) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:13);
- (4) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:14);
- (5) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:15);
- (6) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:16);
- (7) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:17);
- (8) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:18);
- (9) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:19);
- (10) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:20);
- (11) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:21);
- (12) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:22);
- (13) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:23);
- (14) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:24);
- (15) DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:25);
- (16) Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:26);
- (17) Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:27);
- (18) Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:28);
- (19) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:29);
- (20) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg (SEQ ID NO:30);
- (21) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu (SEQ ID NO:31);
- (22) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:32);
- (23) Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:33);
- (24) Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:34);
- (25) DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:35);
- (26) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:36);
- (27) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:37);
- (28) Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:38);
- (29) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:39);
- (30) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:40);


- (31) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:41);
- (32) guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:42);
- (33) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:43);
- (34) TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:44);
- (35) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:45);
- (36) 2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:46);
- (37) APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:47);
- (38) desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:48);
- (39) guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:49);
- (40) succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:50);
- (41) glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:51);
- (42) deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:52);
- (43) nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:53);
- (44) AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:54);
- (45) R-CH<sub>2</sub>-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:55);
- (46) Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:56);
- (47) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:57);
- (48) ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:58);
- (49) ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:59);
- (50) Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:60);
- (51) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:61);
- (52) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:62);
- (53) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:63);
- (54) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64);
- (55) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe (SEQ ID NO:65);
- (56) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt (SEQ ID NO:66);
- (57) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr (SEQ ID NO:67); or
- (58) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine (SEQ ID NO:68);

wherein,


in each of peptides (1)-(58), the designation appearing before the N-terminal amino acid represents a chemical derivative of the  $\alpha$ -amino nitrogen, Ac is acetyl, TMguanyl is tetra-methyl guanyl, 2F-benzoyl is 2-fluorobenzoyl, 4F-benzoyl is 4-fluorobenzoyl, APA is 5-amino-pentanoyl, ACA is 6-amino-hexanoyl, desamino-R is 2-desamino-arginyl, deaminoTMG-APA is formula (II),




nelfinaviryl-succinyl is formula (III),



AZT-glutaryl is formula (IV),



R-CH<sup>2</sup> is the formula (V)



the amino acids are abbreviated as follows: Arg is L-arginine, Nal is L-3-(2-naphthyl)alanine, Cys is L-cysteine, Tyr is L-tyrosine, Cit is L-citrulline, Lys is L-lysine, DLys is D-lysine, Pro is L-proline, DCit is D-citrulline, DGlu is D-glutamic acid, Glu is L-glutamic acid;


the two cysteine residues in each peptide are bonded by an intramolecular disulfide bond, and the designation after the C-terminal amino acid represents a chemical derivative of the terminal carboxyl group, NH<sub>2</sub> represents amidation by an amino group, NHMe represents amidation by a methylamino group, NH<sub>2</sub>Et represents amidation by an ethylamino group, and NHiPr represents amidation by an isopropylamino group.

15. *(previously presented)*: A pharmaceutical composition comprising:

- (a) a peptide according to claim 1 or a salt thereof; and
- (b) a pharmaceutically acceptable carrier or excipient.

**16. CANCELLED**

17. *(currently amended)*: A method for ~~preventing or treating~~ or ameliorating cancers, or chronic rheumatoid arthritis in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a peptide according to formula (I) or a salt thereof:



wherein:

amino acid positions are numbered 1-14 and each amino acid may be a D- or L-amino acid;

A1 is arginine, lysine, ornithine, citrulline, alanine or glutamic acid or a derivative thereof derivatized at the N-terminus~~α-amino-nitrogen~~, or A1 is absent;

A2 is arginine or glutamic acid when A1 is arginine, lysine, ornithine, citrulline, alanine or glutamic acid, or

if A1 is absent, A2 is arginine or glutamic acid which is optionally derivatized at the N-terminus~~α-amino-nitrogen~~;

A3 is an aromatic amino acid;

A4 and A5 independently are arginine, lysine, ornithine, citrulline, alanine or glutamic acid;

A6 is proline, glycine, ornithine, lysine, alanine, citrulline, arginine or glutamic acid;

A7 is proline, glycine, ornithine, lysine, alanine, citrulline or arginine;

A8 is tyrosine, phenylalanine, alanine, naphthylalanine, citrulline or glutamic acid;

A9 is arginine, lysine, ornithine, citrulline, alanine or glutamic acid;

A10 is citrulline, glutamic acid, arginine or lysine;

A11 is arginine, glutamic acid, lysine or citrulline or a C-terminal derivative thereof; and the cysteine residues at positions 4 and 11 are optionally disulfide-bonded .

18. *(previously presented)*: The method according to claim 17 wherein the cancer is breast cancer or pancreatic cancer.

**19 - 22. CANCELLED**

23. *(previously presented)* The peptide according to claim 14 numbered (35) and (54) having, respectively, the sequence as set forth in SEQ ID NO:45 or in SEQ ID NO:64.
24. *(currently amended)*: The pharmaceutical composition according to claim 15, wherein:  
A1 is arginine, citrulline, alanine or glutamic acid which is derivatized at the N-terminus~~α-amino nitrogen~~, or A1 is deleted;  
A2 is arginine or glutamic acid when A1 is arginine, citrulline, alanine or glutamic acid derivatized at the N-terminus~~α-amino nitrogen~~, or  
if A1 is absent, A2 is arginine or glutamic acid which is derivatized at the N-terminus~~α-amino nitrogen~~;  
A4 is arginine, citrulline, alanine or glutamic acid;  
A5 is arginine, citrulline, alanine, lysine or glutamic acid;  
A6 is lysine, alanine, citrulline or glutamic acid;  
A7 is proline or alanine;  
A8 is tyrosine, alanine or glutamic acid;  
A9 is arginine, citrulline or glutamic acid residue;  
A10 is citrulline or glutamic acid;  
A11 is arginine or glutamic acid or a C-terminal derivative thereof.
25. *(withdrawn; currently amended)*: The pharmaceutical composition according to claim 15, wherein A1 is glutamic acid derivatized at the N-terminus~~α-amino nitrogen~~, or A1 is absent.
26. *(withdrawn; currently amended)*: The pharmaceutical composition according to claim 15, wherein any one of A2, A4, A6, A8 and A9 is glutamic acid.
27. *(withdrawn)*: The pharmaceutical composition according to claim 15, wherein A5 is arginine or glutamic acid.
28. *(withdrawn)*: The pharmaceutical composition according to claim 15, wherein A5 is glutamic acid.
29. *(withdrawn)*: The pharmaceutical composition according to claim 15, wherein A10 is glutamic acid, arginine or lysine.
30. *(withdrawn)*: A pharmaceutical composition according to claim 15, wherein A11 is glutamic acid, lysine or citrulline.

31. (withdrawn): A pharmaceutical composition comprising:

- (a) a pharmaceutically acceptable carrier or excipient; and
- (b) a peptide having the sequence as set forth in any one of SEQ ID NO's: 11-68 or a salt thereof:
  - (1) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:11);
  - (2) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:12);
  - (3) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:13);
  - (4) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:14);
  - (5) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:15);
  - (6) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:16);
  - (7) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:17);
  - (8) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:18);
  - (9) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:19);
  - (10) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:20);
  - (11) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:21);
  - (12) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:22);
  - (13) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:23);
  - (14) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:24);
  - (15) DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:25);
  - (16) Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:26);
  - (17) Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:27);
  - (18) Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:28);
  - (19) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:29);
  - (20) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg (SEQ ID NO:30);
  - (21) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu (SEQ ID NO:31);
  - (22) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:32);
  - (23) Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:33);
  - (24) Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:34);
  - (25) DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:35);
  - (26) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:36);
  - (27) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:37);
  - (28) Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:38);
  - (29) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:39);
  - (30) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:40);
  - (31) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:41);
  - (32) guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:42);
  - (33) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:43);
  - (34) TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:44);
  - (35) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:45);
  - (36) 2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:46);
  - (37) APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:47);



- (38) desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:48);
- (39) guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:49);
- (40) succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:50);
- (41) glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:51);
- (42) deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:52);
- (43) nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:53);
- (44) AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:54);
- (45) R-CH<sub>2</sub>-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:55);
- (46) Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:56);
- (47) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:57);
- (48) ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:58);
- (49) ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:59);
- (50) Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:60);
- (51) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:61);
- (52) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:62);
- (53) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:63);
- (54) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64);
- (55) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe (SEQ ID NO:65);
- (56) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt (SEQ ID NO:66);
- (57) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NhiPr (SEQ ID NO:67);
- (58) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine (SEQ ID NO:68).

32. *(withdrawn)*: The pharmaceutical composition according to claim 31, comprising the peptide numbered (35) and (54) having, respectively, the sequence as set forth in SEQ ID NO:45 or in SEQ ID NO:64.

33. *(previously presented)*: The method according to claim 17, wherein said peptide is a CXCR4 antagonist.

34. *(currently amended)*: The method according to claim 17, wherein ~~the  $\alpha$ -amino group of~~ the N-terminal amino acid is derivatized by a substituted benzoyl group selected from the group consisting of 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-bromobenzoyl, 3-bromobenzoyl, 4-bromobenzoyl, 2-nitrobenzoyl, 3-nitrobenzoyl, and 4-nitrobenzoyl.

35. *(previously presented)*: The method according to claim 34, wherein the substituted benzoyl group is as a 4-fluorobenzoyl or a 2-fluorobenzoyl group .

**36 to 38. CANCELLED**

39. (*withdrawn; currently amended*): A method for ~~preventing or treating~~ or ameliorating cancers or chronic rheumatoid arthritis in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a peptide the sequence of which is set forth in any one of SEQ ID NOs: 11-68, or a salt thereof:

- (1) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:11);
- (2) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:12);
- (3) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:13);
- (4) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:14);
- (5) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:15);
- (6) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:16);
- (7) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:17);
- (8) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg (SEQ ID NO:18);
- (9) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:19);
- (10) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:20);
- (11) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:21);
- (12) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:22);
- (13) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:23);
- (14) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:24);
- (15) D<sup>Glu</sup>-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:25);
- (16) Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:26);
- (17) Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:27);
- (18) Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:28);
- (19) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:29);
- (20) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg (SEQ ID NO:30);
- (21) Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu (SEQ ID NO:31);
- (22) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:32);
- (23) Arg-Arg-Nal-Cys-Tyr-D<sup>Glu</sup>-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:33);
- (24) Arg-Arg-Nal-Cys-Tyr-D<sup>Glu</sup>-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:34);
- (25) D<sup>Glu</sup>-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:35);
- (26) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-D<sup>Glu</sup>-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:36);
- (27) Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-D<sup>Glu</sup>-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:37);
- (28) Ac-D<sup>Glu</sup>-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:38);
- (29) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-D<sup>Glu</sup>-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:39);
- (30) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-D<sup>Glu</sup>-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:40);
- (31) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:41);
- (32) guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:42);
- (33) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:43);
- (34) TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:44);
- (35) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:45);
- (36) 2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D<sup>Glu</sup>-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:46);

- (37) APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:47);
- (38) desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:48);
- (39) guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:49);
- (40) succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:50);
- (41) glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:51);
- (42) deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:52);
- (43) nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:53);
- (44) AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:54);
- (45) R-CH<sub>2</sub>-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:55);
- (46) Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:56);
- (47) TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:57);
- (48) ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:58);
- (49) ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg (SEQ ID NO:59);
- (50) Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:60);
- (51) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:61);
- (52) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:62);
- (53) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:63);
- (54) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64);
- (55) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe (SEQ ID NO:65);
- (56) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt (SEQ ID NO:66);
- (57) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NhiPr (SEQ ID NO:67);
- (58) 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine (SEQ ID NO:68).

40. *(withdrawn)*: The method according to claim 39 wherein the sequence of said peptide is SEQ ID NO:45 or SEQ ID NO:64.

41. *(withdrawn)*: The method of claim 39 wherein said subject is afflicted with cancer.

42. *(withdrawn)*: The method of claim 39 wherein said subject is afflicted with chronic rheumatoid arthritis.

43. *(withdrawn)*: The peptide or salt of claim 1, wherein the sequence of said peptide is any one of SEQ ID NO:45, 46, and SEQ ID NOs: 64-68.

44. *(withdrawn)*: The pharmaceutical composition of claim 15, wherein the sequence of said peptide is any one of SEQ ID NO:45, SEQ ID NO:46, and SEQ ID NOs:64-68.

45. *(withdrawn)*: The method of claim 35, wherein the sequence of said peptide is any one of SEQ ID NO:45, SEQ ID NO:46, and SEQ ID NOs:64-68.

46. (*new*): The peptide or salt of claim 1, wherein the derivatizing substituted benzoyl group is a 4-fluorobenzoyl or a 2-fluorobenzoyl group.
47. (*new*) The peptide or salt of claim 46, wherein the peptide is  
4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64).
- 48.. (*new*): The pharmaceutical composition of claim 15, wherein the derivatizing substituted benzoyl group is a 4-fluorobenzoyl group or a 2-fluorobenzoyl group.
49. (*new*) The pharmaceutical composition of claim 48 wherein the peptide is  
4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64)  
or said salt thereof.
50. (*new*): The method of claim 17, wherein the derivatizing substituted benzoyl group is a 4-fluorobenzoyl group or a 2-fluorobenzoyl group.
51. (*new*) The method of claim 50, wherein the pharmaceutical composition comprises as said active ingredient a therapeutically effective amount of the peptide  
4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (SEQ ID NO:64).  
or said salt thereof.
52. (*new*): The method of claim 17, wherein the method inhibits cancer metastasis.